Leqvio (Inclisiran) Renal Protection or Renal Risk: What the Evidence Shows

Does inclisiran need a different dose in kidney disease?

No. The current Leqvio label, effective 19 August 2026, gives a single regimen of 284 mg subcutaneously, again at 3 months, then every 6 months, and states that no dose adjustment is required for mild, moderate or severe renal impairment [1]. The same label states that inclisiran has not been studied in end-stage renal disease [1].

Severe renal impairment sits inside the no-adjustment language. Dialysis and end-stage disease sit outside the studied population.

What kidney disease does to inclisiran exposure

About 16% of an inclisiran dose is cleared through the kidney [1]. In the renal-impairment study described in the label, peak plasma concentration was 2.3 to 3.3 times higher and total exposure 1.6 to 2.3 times higher in people with mild, moderate or severe renal impairment than in people with normal kidney function, yet LDL-C reductions were similar across all groups [1].

A population analysis of 4,328 patients found that age, body weight, sex, race and creatinine clearance did not significantly affect inclisiran pharmacokinetics [1].

Plasma levels peak about 4 hours after a subcutaneous dose and are undetectable by 24 to 48 hours, with a terminal half-life of about 9 hours and no accumulation on repeat dosing [1]. The drug is taken up by the liver, and LDL-C stays reduced for months after a dose [1].

ORION-7, the dedicated renal-impairment study

ORION-7 (NCT03159416) was a phase 1 study of 31 participants with normal kidney function or mild, moderate or severe renal impairment, who received 300 mg of inclisiran sodium or placebo [3].

At day 60, LDL-C fell significantly versus placebo in every group: 57.6% with normal kidney function, 35.1% with mild impairment, 53.1% with moderate impairment and 49.2% with severe impairment [3]. PCSK9 fell by 68.1%, 74.2%, 79.8% and 67.9% respectively [3]. Exposure rose as renal function fell, but inclisiran was undetectable in plasma 48 hours after dosing in every group [3]. The investigators concluded that pharmacodynamic effects and safety were similar across groups and that dose adjustment was not required [3].

It was a small study, and it reported drug levels, PCSK9 and LDL-C rather than kidney outcomes.

What the pooled phase 3 analysis shows

A 2026 post hoc analysis pooled 3,660 participants from ORION-9, ORION-10 and ORION-11 and sorted them by baseline eGFR: 1,610 at 90 or above, 1,608 at 60 to under 90, 300 at 45 to under 60, and 142 at 15 to under 45 mL/min/1.73 m² [2].

At day 510, placebo-corrected LDL-C changes were -49.9%, -51.2%, -54.7% and -44.7% in those four groups, each P<0.001 [2]. The time-adjusted changes from day 90 through day 540 were -48.4%, -51.8%, -55.6% and -50.4% [2]. Total cholesterol, apolipoprotein B, non-HDL cholesterol and lipoprotein(a) fell in every eGFR group, and the authors reported that inclisiran was well tolerated without new safety findings [2].

This is a post hoc subgroup analysis of trials designed around cholesterol, not kidney outcomes [2]. The lowest group stops at 15, so the results do not describe people below that level or on dialysis.

Real-world data in 32 patients with CKD

An observational study followed 32 adults with chronic kidney disease and chronic ischemic heart disease who received inclisiran 284 mg at baseline, 3 months and 6 months [4]. Mean age was 60.2 years, mean baseline LDL-C was 138 mg/dL and mean eGFR was about 37 mL/min/1.73 m² [4]. After 12 months, total and LDL cholesterol had fallen by almost 50%, eGFR had not changed significantly, one patient had a myocardial infarction at 11 months, and no drug-related side effects were reported [4].

With 32 people, no control group and one year of follow-up, this study cannot establish renal safety or renal benefit.

Is there evidence that inclisiran protects the kidneys?

The trials were built to answer a cholesterol question. ORION-9, ORION-10 and ORION-11 measured LDL-C and safety, and ORION-7 measured pharmacokinetics, PCSK9 and LDL-C in renal impairment [5][3][2]. None of these reported effects on eGFR decline, progression to dialysis or albuminuria.

The pooled-analysis authors note that lowering LDL-C reduces atherosclerotic cardiovascular risk in patients with CKD [2]. The label's cardiovascular outcomes statement describes LDL-C lowering with statins or PCSK9 monoclonal antibodies, not inclisiran itself [1]. A kidney-protection claim would need kidney endpoints.

The stable eGFR over 12 months in the 32-patient report [4] cannot separate a drug effect from the natural course of chronic kidney disease.

Is there a kidney-specific risk on the label?

The label has no boxed warning, and its only warning and precaution is hypersensitivity: anaphylaxis and angioedema have been reported, along with rash, pruritus and urticaria in postmarketing reports [1]. A prior serious hypersensitivity reaction to inclisiran or an excipient is a contraindication [1]. The label advises patients to seek medical attention promptly for signs of a hypersensitivity reaction [1].

In the pooled adult placebo-controlled trials (1,833 on Leqvio, 1,822 on placebo), injection site reactions occurred in 8% versus 2%, arthralgia in 5% versus 4%, and bronchitis in 4% versus 3%; 2.5% of inclisiran-treated patients and 1.9% of placebo-treated patients discontinued for adverse reactions [1].

Inclisiran is not a substrate for CYP450 enzymes or transporters and is not expected to cause or be affected by interactions through those pathways [1].

None of these findings is kidney-specific. The renal safety picture rests on the exposure data and the eGFR subgroup results described above.